Pharmaceutical compositions comprising meloxicam
AssigneeAxsome Therapeutics, Inc.
InventorHerriot Tabuteau
Life of this patent
Estimating the term…
Abstract
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of meloxicam and/or rizatriptan for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura.
Claims26
A method of treating migraine, comprising administering a tablet containing about 20 mg of meloxicam, and about 14.5 mg of rizatriptan benzoate to a human patient for the acute treatment of migraine, wherein the human patient has a clear diagnosis of migraine, wherein the human patient does not have moderate to severe renal impairment, wherein the maximum daily dose does not exceed one tablet, and wherein no more than 7 migraines are treated in a 30-day period.
(canceled)
(canceled)
A method of treating migraine, comprising administering a tablet containing about 20 mg of meloxicam, and about 14.5 mg of rizatriptan benzoate to a human patient for the acute treatment of migraine, wherein the human patient has a clear diagnosis of migraine, wherein the human patient has been screened for renal impairment, wherein the maximum daily dose does not exceed one tablet, and wherein no more than 7 migraines are treated in a 30-day period.
(canceled)
(canceled)
A method of treating migraine, comprising administering a tablet containing about 20 mg of meloxicam, and about 14.5 mg of rizatriptan benzoate to a human patient for the acute treatment of migraine, wherein the human patient has a clear diagnosis of migraine, wherein the human patient does not have hepatic impairment, wherein the maximum daily dose does not exceed one tablet, and wherein no more than 7 migraines are treated in a 30-day period.
(canceled)
(canceled)
A method of treating migraine, comprising administering a tablet containing about 20 mg of meloxicam, and about 14.5 mg of rizatriptan benzoate to a human patient for the acute treatment of migraine, wherein the human patient has a clear diagnosis of migraine, wherein the human patient has been screened for hepatic impairment, wherein the maximum daily dose does not exceed one tablet, and wherein no more than 7 migraines are treated in a 30-day period.
(canceled)
(canceled)
Dependencies are inferred from the claim text.